TABLE 3.

In vitro susceptibilities of opportunistic non-Candida yeast-like fungi to new and established antifungal agents determined by NCCLS M27-A2 broth dilution MIC methodsa

SpeciesAntifungal agentNo. of isolates testedMIC (μg/ml)Reference
Range50%90%
T. asahiiAmphotericin B431-8442
Fluconazole430.25-16282
Itraconazole430.06-40.512
Ravuconazole240.25->160.5NAb75
Posaconazole240.06->160.12NA75
Voriconazole240.03->160.25NA75
Non-T. asahiiAmphotericin B150.06-10.25NA75
Fluconazole150.5-42NA75
Itraconazole150.03-0.50.12NA75
Ravuconazole150.03->160.5NA75
Posaconazole150.03-0.50.12NA75
Voriconazole150.03-0.250.06NA75
T. beigeliiAmphotericin B50.5-22NDc25
Fluconazole51-22ND25
Itraconazole50.06-0.250.25ND25
Posaconazole50.12-11ND24
Voriconazole5<0.03-0.12<0.03ND25
Caspofungin516->16>16ND24
Anidulafungin5>16>16ND24
Rhodotorula spp.Amphotericin B350.12-0.50.250.528
Flucytosine350.06-0.250.120.2528
Fluconazole3532-25625625628
Itraconazole350.25-11128
Posaconazole540.25->82421
Ravuconazole560.015-20.25121
Voriconazole550.25->82421
Caspofungin558->8>8>821
Micafungin10>64>64>64113
Geotrichum capitatumAmphotericin B230.06-0.250.120.1230
Flucytosine230.12-160.12430
Fluconazole231-328830
Itraconazole230.03-0.50.120.2530
Voriconazole230.03-0.50.250.2530
Anidulafungin41-44ND6
  • a Testing was performed as described in reference 67.

  • b NA, not available.

  • c ND, not done.